Why did the FDA accelerate approve BMS iberdomide triplet for multiple myeloma?

The FDA granted accelerated approval to Bristol-Myers Squibb’s iberdomide (Zenbexus) with daratumumab/hyaluronidase-fihj and dexamethasone for adults with multiple myeloma after at least one prior therapy. The decision was based on the EXCALIBER-RRMM trial, where the iberdomide arm showed a 41% MRD-negative complete response rate versus 21% for DVd.